keyword
MENU ▼
Read by QxMD icon Read
search

Cannabidiol

keyword
https://www.readbyqxmd.com/read/27932991/cannabidiol-modulates-the-immunophenotype-and-inhibits-the-activation-of-the-inflammasome-in-human-gingival-mesenchymal-stem-cells
#1
Rosaliana Libro, Domenico Scionti, Francesca Diomede, Marco Marchisio, Gianpaolo Grassi, Federica Pollastro, Adriano Piattelli, Placido Bramanti, Emanuela Mazzon, Oriana Trubiani
Human Gingival Mesenchymal Stem Cells (hGMSCs) are multipotential cells that can expand and differentiate in culture under specific and standardized conditions. In the present study, we have investigated whether in vitro pre-treatment of hGMSCs with Cannabidiol (CBD) can influence their expression profile, improving the therapeutic potential of this cell culture. Following CBD treatment (5 μM) for 24 h, gene expression analysis through Next Generation Sequencing (NGS) has revealed several genes differentially expressed between CBD-treated hGMSCs (CBD-hGMSCs) and control cells (CTR-hGMSCs) that were linked to inflammation and apoptosis...
2016: Frontiers in Physiology
https://www.readbyqxmd.com/read/27932983/cannabidiol-regulation-of-learned-fear-implications-for-treating-anxiety-related-disorders
#2
Regimantas Jurkus, Harriet L L Day, Francisco S Guimarães, Jonathan L C Lee, Leandro J Bertoglio, Carl W Stevenson
Anxiety and trauma-related disorders are psychiatric diseases with a lifetime prevalence of up to 25%. Phobias and post-traumatic stress disorder (PTSD) are characterized by abnormal and persistent memories of fear-related contexts and cues. The effects of psychological treatments such as exposure therapy are often only temporary and medications can be ineffective and have adverse side effects. Growing evidence from human and animal studies indicates that cannabidiol, the main non-psychotomimetic phytocannabinoid present in Cannabis sativa, alleviates anxiety in paradigms assessing innate fear...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27918106/cannabidiol-activates-neuronal-precursor-genes-in-human-gingival-mesenchymal-stromal-cells
#3
Thangavelu Soundara Rajan, Sabrina Giacoppo, Domenico Scionti, Francesca Diomede, Gianpaolo Grassi, Federica Pollastro, Adriano Piattelli, Placido Bramanti, Emanuela Mazzon, Oriana Trubiani
In the last years, mesenchymal stromal cells (MSCs) from oral tissues have received considerable interest in regenerative medicine since they can be obtained with minimal invasive procedure and exhibit immunomodulatory properties. This study was aimed to investigate whether in vitro pre-treatment of MSCs obtained from human gingiva (hGMSCs) with Cannabidiol (CBD), a cannabinoid component produced by the plant Cannabis sativa, may promote human gingiva derived MSCs to differentiate towards neuronal precursor cells...
December 5, 2016: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/27899456/free-and-glucuronide-whole-blood-cannabinoids-pharmacokinetics-after-controlled-smoked-vaporized-and-oral-cannabis-administration-in-frequent-and-occasional-cannabis-users-identification-of-recent-cannabis-intake
#4
Matthew N Newmeyer, Madeleine J Swortwood, Allan J Barnes, Osama A Abulseoud, Karl B Scheidweiler, Marilyn A Huestis
BACKGROUND: There is increasing interest in markers of recent cannabis use because following frequent cannabis intake, Δ(9)-tetrahydrocannabinol (THC) may be detected in blood for up to 30 days. The minor cannabinoids cannabidiol, cannabinol (CBN), and THC-glucuronide were previously detected for ≤2.1 h in frequent and occasional smokers' blood after cannabis smoking. Cannabigerol (CBG), Δ(9)-tetrahydrocannabivarin (THCV), and 11-nor-9-carboxy-THCV might also be recent use markers, but their blood pharmacokinetics have not been investigated...
December 2016: Clinical Chemistry
https://www.readbyqxmd.com/read/27890794/target-regulation-of-pi3k-akt-mtor-pathway-by-cannabidiol-in-treatment-of-experimental-multiple-sclerosis
#5
Sabrina Giacoppo, Federica Pollastro, Gianpaolo Grassi, Placido Bramanti, Emanuela Mazzon
This study was aimed to investigate whether treatment with purified cannabidiol (CBD) may counteract the development of experimental multiple sclerosis (MS), by targeting the PI3K/Akt/mTOR pathway. Although the PI3K/Akt/mTOR pathway was found to be activated by cannabinoids in several immune and non-immune cells, currently, there is no data about the effects of CBD in the PI3K/Akt/mTOR activity in MS. Experimental Autoimmune Encephalomyelitis (EAE), the most common model of MS, was induced in C57BL/6 mice by immunization with myelin oligodendroglial glycoprotein peptide (MOG)35-55...
November 25, 2016: Fitoterapia
https://www.readbyqxmd.com/read/27889412/cannabidiol-reduces-neuroinflammation-and-promotes-neuroplasticity-and-functional-recovery-after-brain-ischemia
#6
Marco Aurélio Mori, Erika Meyer, Ligia Mendes Soares, Humberto Milani, Francisco Silveira Guimarães, Rúbia Maria Weffort de Oliveira
This study investigated the effects of cannabidiol (CBD), a non-psychotomimetic phytochemical present in Cannabis sativa, on the cognitive and emotional impairments induced by bilateral common carotid artery occlusion (BCCAO) in mice. Using a multi-tiered behavioral testing battery during 21days, we found that BCCAO mice exhibited long-lasting functional deficits reflected by increase in anxiety-like behavior (day 9), memory impairments (days 12-18) and despair-like behavior (day 21). Short-term CBD 10mg/kg treatment prevented the cognitive and emotional impairments, attenuated hippocampal neurodegeneration and white matter (WM) injury, and reduced glial response that were induced by BCCAO...
November 23, 2016: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/27884751/a-systematic-review-of-the-effect-of-cannabidiol-on-cognitive-function-relevance-to-schizophrenia
#7
REVIEW
Ashleigh L Osborne, Nadia Solowij, Katrina Weston-Green
BACKGROUND AND OBJECTIVES: Cognitive impairment is a core symptom domain of schizophrenia, neurological disorders and substance abuse. It is characterised by deficits in learning, memory, attention and executive functioning and can severely impact daily living. Antipsychotic drugs prescribed to treat schizophrenia provide limited cognitive benefits and novel therapeutic targets are required. Cannabidiol (CBD), a component of the cannabis plant, has anti-inflammatory and antipsychotic-like properties; however, its ability to improve cognitive impairment has not been thoroughly explored...
November 21, 2016: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/27877130/cannabidiol-as-a-potential-new-type-of-an-antipsychotic-a-critical-review-of-the-evidence
#8
REVIEW
Cathrin Rohleder, Juliane K Müller, Bettina Lange, F M Leweke
There is urgent need for the development of mechanistically different and less side-effect prone antipsychotic compounds. The endocannabinoid system has been suggested to represent a potential new target in this indication. While the chronic use of cannabis itself has been considered a risk factor contributing to the development of schizophrenia, triggered by the phytocannabinoid delta-9-tetrahydrocannabinol (Δ(9)-THC), cannabidiol, the second most important phytocannabinoid, appears to have no psychotomimetic potential...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27874495/evolution-of-multiple-sclerosis-spasticity-associated-symptoms-latest-data
#9
Peter Flachenecker
In addition to muscle stiffness and increasing mobility restrictions, symptoms commonly associated with multiple sclerosis (MS) spasticity are spasms, sleep disturbances, pain, fatigue and bladder dysfunction. Treatment options include trigger factor avoidance, physiotherapy and antispasticity medication. Oral antispasticity agents commonly used in Germany are baclofen, tizanidine and gabapentin, but physician and patient satisfaction with their effectiveness is low. Over the past few years, randomized controlled trials, observational studies and registry data have demonstrated the positive risk:benefit profile of add-on 9-delta-tetra-hydrocannabinol:cannabidiol oromucosal spray for moderate-to-severe resistant MS spasticity...
December 2016: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/27865421/cannabidiol-cbd-induces-functional-tregs-in-response-to-low-level-t-cell-activation
#10
Saphala Dhital, John V Stokes, Nogi Park, Keun Seok Seo, Barbara L F Kaplan
Many effects of the non-psychoactive cannabinoid, cannabidiol (CBD), have been described in immune responses induced by strong immunological stimuli. It has also been shown that CBD enhances IL-2 production in response to low-level T cell stimulation. Since IL-2, in combination with TGF-β1, are critical for Treg induction, we hypothesized that CBD would induce CD4(+)CD25(+)FOXP3(+) Tregs in response to low-level stimulation. Low-level T cell stimulation conditions were established based on minimal CD25 expression in CD4(+) cells using suboptimal PMA/Io (4nM/0...
November 9, 2016: Cellular Immunology
https://www.readbyqxmd.com/read/27857623/cannabidiol-mellows-out-resurgent-sodium-current
#11
Christopher H Thompson, Jennifer A Kearney
No abstract text is available yet for this article.
November 2016: Epilepsy Currents
https://www.readbyqxmd.com/read/27856160/anti-excitotoxic-effects-of-cannabidiol-are-partly-mediated-by-enhancement-of-ncx2-and-ncx3-expression-in-animal-model-of-cerebral-ischemia
#12
Sepideh Khaksar, Mohammad Reza Bigdeli
Excitotoxicity and imbalance of sodium and calcium homeostasis trigger pathophysiologic processes in cerebral ischemia which can accelerate neuronal death. Neuroprotective role of cannabidiol (CBD), one of the main non-psychoactive phytocannabinoids of the cannabis plant, has attracted attention of many researchers in the neurodegenerative diseases studies. The present investigation was designed to determine whether cannabidiol can alleviate the severity of ischemic damages and if it is able to exert its anti-excitotoxic effects through sodium and calcium regulation...
November 14, 2016: European Journal of Pharmacology
https://www.readbyqxmd.com/read/27821713/quantitative-analyses-of-synergistic-responses-between-cannabidiol-and-dna-damaging-agents-on-the-proliferation-and-viability-of-glioblastoma-and-neural-progenitor-cells-in-culture
#13
Liting Deng, Lindsay Ng, Tatsuya Ozawa, Nephi Stella
Evidence suggests that the non-psychotropic cannabis-derived compound, cannabidiol (CBD), has anti-neoplastic activity in multiple types of cancers, including glioblastoma multiforme (GBM). DNA-damaging agents remain the main standard of care treatment available for patients diagnosed with GBM. Here we studied the anti-proliferative and cell-killing activity of CBD alone and in combination with DNA-damaging agents (temozolomide, carmustine or cisplatin) in several human GBM cell lines and in mouse primary GBM cells in cultures...
November 7, 2016: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/27815614/cannabinoids-assessment-in-plasma-and-urine-by-high-performance-liquid-chromatography-tandem-mass-spectrometry-after-molecularly-imprinted-polymer-microsolid-phase-extraction
#14
Juan Sánchez-González, Rocío Salgueiro-Fernández, Pamela Cabarcos, Ana María Bermejo, Pilar Bermejo-Barrera, Antonio Moreda-Piñeiro
A molecularly imprinted polymer (MIP) selective for cannabinoids [Δ(9)-tetrahydrocannabinol (Δ9-THC), 11-nor-9-carboxy-Δ(9)-tetrahydrocannabinol (Δ9-THC-COOH), and 11-hydroxy-Δ(9)-tetrahydrocannabinol (Δ9-THC-OH)] has been synthesized, fully characterized, and applied to the assessment of plasma and urine analysis of marijuana abuse by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Δ9-THC-COOH was used as a template molecule, whereas ethylene glycol dimethacrylate (EGDMA) was used as a functional monomer, divinylbenzene (DVB) as a cross-linker, and 2,2'-azobisisobutyronitrile (AIBN) as an initiator...
November 4, 2016: Analytical and Bioanalytical Chemistry
https://www.readbyqxmd.com/read/27811555/targeting-the-endocannabinoid-system-in-psychiatric-illness
#15
Martin A Katzman, Melissa Furtado, Leena Anand
Prevalence of psychiatric disorders continues to rise globally, yet remission rates and patient outcome remain less than ideal. As a result, novel treatment approaches for these disorders are necessary to decrease societal economic burden, as well as increase individual functioning. The recent discovery of the endocannabinoid system has provided an outlet for further research into its role in psychiatric disorders, because efficacy of targeted treatments have been demonstrated in medical illnesses, including cancers, neuropathic pain, and multiple sclerosis...
December 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27798074/stability-of-tetrahydrocannabinol-and-cannabidiol-in-prepared-quality-control-medible-brownies
#16
Carl E Wolf, Justin L Poklis, Alphonse Poklis
The legalization of marijuana in the USA for both medicinal and recreational use has increased in the past few years. Currently, 24 states have legalized marijuana for medicinal use. The US Drug Enforcement Administration has classified marijuana as a Schedule I substance. The US Food and Drug Administration does not regulate formulations or packages of marijuana that are currently marketed in states that have legalized marijuana. Marijuana edibles or "medibles" are typically packages of candies and baked goods consumed for medicinal as well as recreational marijuana use...
October 18, 2016: Journal of Analytical Toxicology
https://www.readbyqxmd.com/read/27790138/splendor-in-the-grass-a-pilot-study-assessing-the-impact-of-medical-marijuana-on-executive-function
#17
Staci A Gruber, Kelly A Sagar, Mary K Dahlgren, Megan T Racine, Rosemary T Smith, Scott E Lukas
Currently, 25 states and Washington DC have enacted full medical marijuana (MMJ) programs while 18 states allow limited access to MMJ products. Limited access states permit low (or zero) tetrahydrocannabinol (THC) and high cannabidiol (CBD) products to treat specified conditions such as uncontrolled epilepsy. Although MMJ products are derived from the same plant species as recreational MJ, they are often selected for their unique cannabinoid constituents and ratios, not typically sought by recreational users, which may impact neurocognitive outcomes...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27772772/cortical-and-spinal-excitability-in-patients-with-multiple-sclerosis-and-spasticity-after-oromucosal-cannabinoid-spray
#18
Giovanna Squintani, Francesco Donato, Mara Turri, Luciano Deotto, Francesco Teatini, Giuseppe Moretto, Roberto Erro
BACKGROUND: Delta-9-tetrahydrocannabinol and cannabidiol (THC:CBD) oromucosal spray (Sativex®) has been recently approved for the management of treatment-resistant multiple sclerosis (MS) spasticity. Although the symptomatic relief of Sativex® on MS-spasticity has been consistently demonstrated, the pathogenetic implications remain unclear and the few electrophysiological studies performed to address this topic yielded controversial results. We therefore aimed to investigate the mechanisms underpinning the modulation of spastic hypertonia by Sativex®, at both central and spinal levels, through an extensive neurophysiological battery in patients with MS...
November 15, 2016: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/27769052/cannabinoids-synergize-with-carfilzomib-reducing-multiple-myeloma-cells-viability-and-migration
#19
Massimo Nabissi, Maria Beatrice Morelli, Massimo Offidani, Consuelo Amantini, Silvia Gentili, Alessandra Soriani, Claudio Cardinali, Pietro Leoni, Giorgio Santoni
Several studies showed a potential anti-tumor role for cannabinoids, by modulating cell signaling pathways involved in cancer cell proliferation, chemo-resistance and migration. Cannabidiol (CBD) was previously noted in multiple myeloma (MM), both alone and in synergy with the proteasome inhibitor bortezomib, to induce cell death. In other type of human cancers, the combination of CBD with Δ9-tetrahydrocannabinol (THC) was found to act synergistically with other chemotherapeutic drugs suggesting their use in combination therapy...
October 18, 2016: Oncotarget
https://www.readbyqxmd.com/read/27768570/effectiveness-of-cannabidiol-oil-for-pediatric-anxiety-and-insomnia-as-part-of-posttraumatic-stress-disorder-a-case-report
#20
Scott Shannon, Janet Opila-Lehman
INTRODUCTION: Anxiety and sleep disorders are often the result of posttraumatic stress disorder and can contribute to an impaired ability to focus and to demonstration of oppositional behaviors. CASE PRESENTATION: These symptoms were present in our patient, a ten-year-old girl who was sexually abused and had minimal parental supervision as a young child under the age of five. Pharmaceutical medications provided partial relief, but results were not long-lasting, and there were major side effects...
2016: Permanente Journal
keyword
keyword
1686
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"